ReviewBone marrow transplantation2003
Post-transplant lymphoproliferative disorder: a review.
Review in Bone marrow transplantation, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
75 citing papers in PubMed, 2 syntheses or guidelines pooled it, 265 citations in OpenAlex.
- Donor-transmitted cancer in kidney transplant recipients: a systematic review.Journal of nephrology · 2020Pooled it
- Pooled it
- Trial
- Risk factors for Epstein-Barr virus-related post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation.Haematologica · 2014Trial
- Global Epidemiology of Post-Transplant Lymphoproliferative Disorder (PTLD) in Hematopoietic Stem Cell Transplantation (HSCT): A Systematic Review and Meta-Analysis of Incidence, Subtypes, Risk Factors, and Beyond.Journal of clinical medicine · 2026Review
- Post-transplant lymphoproliferative disorder after solid organ transplantation: a comprehensive review.Frontiers in transplantation · 2026Review
- Highly sensitive detection of Epstein-Barr virus-infected cells by EBER flow FISH.International journal of hematology · 2024Article
- Burden and frequency of viral testing of kidney and non-kidney transplant recipients.Microbiology spectrum · 2024Article
- Case report: A rare EBV-associated T/NK cell monomorphic posttransplant lymphoproliferative disorder.Frontiers in immunology · 2024Article
- Donor-Derived Leukemia in a Recipient of Double-Unit Cord Blood Transplantation for Acute Myeloid Leukemia: A Case Study and Literature Review.Oncology and therapy · 2022Review
- Characteristics, management, and outcome of pediatric patients with post-transplant lymphoproliferative disease-A 20 years' experience from Austria.Cancer reports (Hoboken, N.J.) · 2021Article
- Epstein-Barr virus induced post-transplant lymphoproliferative disorder presenting with unilateral retinal involvement.American journal of ophthalmology case reports · 2021Article
- Targeted Delivery of BZLF1 to DEC205 Drives EBV-Protective Immunity in a Spontaneous Model of EBV-Driven Lymphoproliferative Disease.Vaccines · 2021Article
- First Successful Delivery after Uterus Transplantation in MHC-Defined Cynomolgus Macaques.Journal of clinical medicine · 2020Article
- Lymphoproliferative disorder in a lung transplant recipient.BMJ case reports · 2020Article
- Article
- An unusual hematopoietic stem cell transplantation for donor acute lymphoblastic leukemia: a case report.BMC cancer · 2020Article
- CDR3α drives selection of the immunodominant Epstein Barr virus (EBV) BRLF1-specific CD8 T cell receptor repertoire in primary infection.PLoS pathogens · 2019Article
- Development of a novel inducer for EBV lytic therapy.Bioorganic & medicinal chemistry letters · 2019Article
- Solitary extramedullary plasmacytoma of the rectum complicating ulcerative colitis.Clinical journal of gastroenterology · 2019Article
15 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Post-transplant lymphoproliferative disorder (PTLD) represents a spectrum of Epstein-Barr virus-related (EBV) clinical diseases, from a benign mononucleosis-like illness to a fulminant non-Hodgkin's lymphoma. In the setting of hematopoietic stem cell transplantation, PTLD is an often-fatal complication occurring relatively early after transplant. Risk factors for the development of PTLD are well established, and include HLA-mismatching, T-cell depletion, and the use of antilymphocyte antibodies as conditioning or treatment of graft-versus-host disease. Early recognition of PTLD is particularly important in the SCT setting, because PTLD in these patients tends to be rapidly progressive. Familiarity with the clinical features of PTLD and a heightened level of suspicion are critical for making the diagnosis. Surveillance techniques with EBV antibody titers and/or polymerase chain reaction (PCR) may have a role in some high-risk settings. Immune-based therapies such as monoclonal anti-B-cell antibodies, interferon-alpha, and EBV-specific donor T cells, either as treatment for PTLD or as prophylaxis in high-risk patients, represent promising new directions in the treatment of this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.